0.1691
0.17 (-22.12%)
As of Mar 06, 2024
Pieris Pharmaceuticals, Inc. [PIRS]
Source:
Company Overview
We are a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in unique and transformative ways. Our clinical pipeline includes an inhaled IL-4Rα antagonist Anticalin protein to treat uncontrolled asthma, an immuno-oncology, or IO, bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB.
Country | United States |
Headquarters | boston, massachusetts |
Phone Number | 857-246-8998 |
Industry | manufacturing |
CEO | Stephen S. Yoder |
Website |